Abstract
Chronic obstructive pulmonary disease (COPD) accounts for one of the major health and economic burdens worldwide. As a heterogeneous disease, the underlying inflammatory pattern of COPD differs from the previously thought neutrophil-dominated inflammation, with eosinophilic inflammation occupying approximately one third of stable COPD. Although the eosinophil (EOS) threshold associated with clinical relevance in patients with COPD is currently debated, eosinophil count can be used as a biomarker to guide treatment and to assess the risk of acute exacerbations of COPD, the efficacy of inhaled corticosteroids, and clinical outcomes. The purpose of this review is to describe the biological characteristics of eosinophils and the related research progress as clinical biomarkers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
